|
 |
| home > pmps > spring 2004 > assessing the implications of the new drug labelling legislation |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The issues surrounding the labelling of pharmaceutical products have generated considerable coverage in the press over the last few months. This upsurge in interest has been sparked by two imminent changes in labelling legislation. The first comes from the FDA and relates to licensed products, while the second change is driven by the European Union and focuses on investigational products. This article will consider the implications these changes will have on the assembly and packaging of pharmaceutical products.
FDA Final Ruling
On 25th February this year, the FDA issued its final ruling on the requirement to include bar codes on the packaging of human drug products and biological products. The motive behind the ruling is the desire to reduce the number of adverse events and transfusion errors that occur - the FDA estimates that this new ruling will prevent over 500,000 such errors over a period of 20 years, with an associated cost saving of billion in the same period.
In some hospitals that are already using bar coding systems, medication error rates have been reduced by as much as 85 per cent and one hospital in the US has administered 5.7 million doses of medication to date without a single error. On the downside, according to the FDA's own figures, the financial impact of this ruling on the pharmaceutical industry is expected to be million in the first two years. Despite this, there has been widespread support for this approach to improving patient safety from health care professionals, hospitals and trade and professional associations alike. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
